Inflammatory condition of skin

This section encompasses a wide range of skin conditions, comprising a number of separate aetiologies. They fall into this category due to their common inflammatory pathology,

...


Read more on Inflammatory condition of skin

 

 

Latest news articles

Drug news

Orencia (abatacept) is CHMP recommended to treat active psoriatic arthritis (PsA).-BMS.

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a change to the terms...

Drug news

Successful SPIRIT- P1 study of Taltz (ixekizumab) to treat psoriatic arthritis.- Eli Lilly

Eli Lilly and Company announced that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab) exhibited...

View all news articles

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis


Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis


Guidelines

Psoriasis overview NICE Pathways

This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.

Canadian Guidelines for the Management of Plaque Psoriasis 2009

Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases. 

Adalimumab for treating moderate to severe hidradenitis suppurativa

Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

View all guidelines

Journal articles

Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.

Palmoplantar pustular psoriasis (PPPP) is a variant of psoriasis, which has significant negative impact on quality of life. The cellular and molecular inflammatory pathways involved in PPPP have not been well studied.

Psoriasis and psoriatic arthritis.

Psoriasis is a dynamic systemic disease that can have a profound affect on a patient's self-esteem.

View all journal articles

Clinical trials

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

View all clinical trials

CME

Psoriasis: diagnosis and individualised therapy

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
15

Ask an expert: Psoriasis

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Psoriasis: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
View all CME